BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22695075)

  • 1. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer.
    Reis ST; Leite KR; Piovesan LF; Pontes-Junior J; Viana NI; Abe DK; Crippa A; Moura CM; Adonias SP; Srougi M; Dall'Oglio MF
    BMC Urol; 2012 Jun; 12():18. PubMed ID: 22695075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer.
    Reis ST; Pontes-Junior J; Antunes AA; de Sousa-Canavez JM; Dall'Oglio MF; Passerotti CC; Abe DK; Crippa A; da Cruz JA; Timoszczuk LM; Srougi M; Leite KR
    Int J Biol Markers; 2011; 26(4):255-61. PubMed ID: 22139647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
    Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
    Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
    Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
    Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.
    Figueira RC; Gomes LR; Neto JS; Silva FC; Silva ID; Sogayar MC
    BMC Cancer; 2009 Jan; 9():20. PubMed ID: 19144199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
    Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
    J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
    Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
    Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer.
    Fouad H; Salem H; Ellakwa DE; Abdel-Hamid M
    J Biochem Mol Toxicol; 2019 Apr; 33(4):e22275. PubMed ID: 30548095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
    Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency.
    Furukawa A; Tsuji M; Nishitani M; Kanda K; Inoue Y; Kanayama H; Kagawa S
    Urology; 1998 May; 51(5):849-53. PubMed ID: 9610608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
    Ozdemir E; Kakehi Y; Okuno H; Yoshida O
    J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer.
    Wieczorek E; Jablonowski Z; Tomasik B; Konecki T; Jablonska E; Gromadzinska J; Fendler W; Sosnowski M; Wasowicz W; Reszka E
    Clin Biochem; 2015 Dec; 48(18):1235-40. PubMed ID: 26197083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
    Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
    Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Grade T1 Papillary Urothelial Bladder Cancer Shows Prominent Peritumoral Retraction Clefting.
    Džombeta T; Krušlin B
    Pathol Oncol Res; 2018 Jul; 24(3):567-574. PubMed ID: 28752222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated expression of matrix metalloproteinase-9 is associated with bladder cancer pathogenesis.
    Wu GJ; Bao JS; Yue ZJ; Zeng FC; Cen S; Tang ZY; Kang XL
    J Cancer Res Ther; 2018; 14(Supplement):S54-S59. PubMed ID: 29578150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas.
    Monier F; Mollier S; Guillot M; Rambeaud JJ; Morel F; Zaoui P
    Eur Urol; 2002 Oct; 42(4):356-63. PubMed ID: 12361901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.